Where is Xi Jinping? Chinese president may skip BRICS Summit, was last seen on..., World leaders say...
New Delhi: Chinese President Xi Jinping is one of the most powerful leaders in the world, who held power in China for many years. Xi Jinping's power and authority has today become unprecedented — it has never been challenged during this time. However, in recent times, Xi Jinping has been noticeably absent. His absence from several major events has surprised many, as he has not been seen participating in any of them. Xi Jinping to Skip BRICS Summit
In a major development, reports suggest that Chinese President Xi Jinping will not be attending the BRICS Summit 2025. It is important to note that the BRICS summit is scheduled to be held in Brazil on July 6. Since 2012, Xi Jinping has been consistently participating in the summit. Keeping Distance from Chinese Media
What's surprising is that while Xi Jinping might skip a conference once in a while, his presence is always felt in Chinese media. All the government mouthpieces there regularly feature his statements. But this time, he seems to be missing from even those outlets. What is the world saying?
Global media is abuzz with speculation. Some reports suggest that Xi Jinping may be encountering serious challenges from opposition leaders, while others hint at health issues possibly linked to his advancing age. However, none of these claims have been officially verified, leaving an air of uncertainty not only within China but around the world.
The last time Xi Jinping was seen was during his meeting with the Prime Minister of Singapore; he appeared before the media on June 24.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India.com
21 minutes ago
- India.com
Bad news for Trump, as China is making close ties with US ally, offers its most dangerous weapons used during Operation Sindoor against India, it is…, country is…
Saudi Arabia has long been regarded as a strong ally of the US. However, in recent years, it has appeared to forge stronger ties with China. The US has reconfigured its efforts to engage with Saudi Arabia by offering NATO-like security arrangements in return for Saudi Arabia's recognition of Israel. But the long war in Gaza has stalled negotiations on this front. On the other hand, China has enhanced its outreach to Saudi Arabia by offering military cooperation. For its part, China has offered to provide J-10 fighter jets to Saudi Arabia, the same aircraft Pakistan falsely claimed was used to shoot down India's Rafale during Operation Sindoor. Which US Ally Is Moving Closer to China? This disinformation was heavily propagated by China, Turkey, and the USA, all acting in their strategic interests. None of these countries could provide any actual evidence for this. China is now taking this same narrative to market its weapons. It has labelled the J-10 fighter jet as a combat-verified aircraft. Despite its effort, no country—including Saudi Arabia—has yet made any formal commitment to purchase the J-10 jets. While speaking to a researcher specializing in Middle East affairs at China's Northwest University stated, 'One of the reasons why Saudi Arabia prefers western weapons over its Chinese equivalent is because Chinese weapons have not seen combat in recent years.' Furthermore, he stated, 'This may change now that the Chinese-made J-10 fighter jet has drawn its first blood.' What Deal Has China Offered? Saudi Arabia has consistently relied on the United States for both its security needs and the sustainability of its petrodollars-driven economy. Due to this, Saudi Arabia remained one of the largest defense buyers of America. However, in recent years, there has been tension in the relationship between the two countries. During Joe Biden's presidency, the U.S. appeared willing to distance itself from Saudi Arabia, most notably by stopping support for its fight against Houthi rebels; even though, at Washington's request, Saudi Arabia had created a military coalition against the Houthis. The U.S. further stressed the relationship by removing air defense systems from the Middle East in order to bolster European security because of the situation with Russia. Consequently, Saudi Arabia has sought alternative partners for defense cooperation to lessen its reliance on Washington. Meanwhile, turning fully away from the dependency on Washington and towards China is still complicated. Seeing an opening, China's intensification in its outreach has included offers of military equipment (i.e., ballistic missiles, drones, howitzers, and air defense systems), at competitive prices and unconditional options. So far, however, Saudi Arabia has exported most of its new defense systems from the United States. In May, the United States and Saudi Arabia finalized a $142 billion arms deal that the White House declared was the 'largest defense sales agreement in history.' The agreement was completed during President Donald Trump's visit to the Kingdom; this visit was the first stop on a four-day tour of the Gulf. It was the first example of the transactional nature of the foreign policy pursued by Trump.
The Print
an hour ago
- The Print
5 yrs, 33 foreign trips: Modi's global outreach cost exchequer Rs 362 cr between 2021 & 2025
The three remaining foreign trips in 2025 include his visit to France and the US in February, a tour of Thailand and Sri Lanka in April, and another trip to Saudi Arabia at the end of April. The combined cost of these three trips was Rs 67 crore. The Prime Minister made 33 trips abroad from 2021 to 2025, and the Rs 362 crore account for foreign visits up to his tour of five nations earlier this month, the data furnished by MoS Kirti Vardhan Singh shows. The bills for three of Modi's foreign visits in 2025—to Canada, where he attended the G7 summit; to Brazil, where he participated in the BRICS summit; and to Mauritius—are not fully settled, so not not included in the calculations. New Delhi: Prime Minister Narendra Modi's foreign visits from 2021 to 2025 cost the exchequer Rs 362 crore, which does not include expenses of his current trip to the UK and the Maldives or unsettled bills, the Minister of State for External Affairs of India informed the Rajya Sabha Thursday. Among these trips, his February tour to France and the United States incurred the highest costs this year. Starting 10 February and lasting till 12 February, his visit to France cost the exchequer Rs 25.59 crore. In the period, Modi co-chaired an Artificial Intelligence Action Summit. On 13 February, he visited the US, and the one-day trip cost Rs 16.54 crore. In France, this year, Modi had at least nine engagements, including the inauguration of the new Indian consulate in Marseille and a scheduled visit to Mazargues War Cemetery. He also had bilateral engagements with French President Emmanuel Macron. In the US, Modi had bilateral engagements with President Donald Trump, followed by dinner. He also held several meetings with American personalities, including Elon Musk, as well as officials. Modi travelled to the US in 2021, 2023, 2024, and 2025, visits that have cumulatively cost Rs 74.41 crore. Among his 2025 trips, the visit to Thailand and Sri Lanka cost slightly over Rs 9 crore. On the other hand, his trip to Saudi Arabia alone cost the exchequer Rs 15.54 crore. Modi, however, had to cut short the trip to the Saudi Arabian city of Jeddah due to the 22 April Pahalgam terror attack. He returned to India before completing the planned two-day visit. His 11 foreign trips in 2024 cost the exchequer Rs 109.5 crore and included visits to 17 countries. At Rs 15.3 crore, a three-day US tour, starting from 21 September 2024, was the most expensive that year. The PM also took his first foreign trip in his third term in 2024, visiting Italy for the G7 summit. It cost Rs 14.36 crore. Overall, 2024 was the second-most expensive year—in terms of the combined cost of his foreign trips—after 2025. In 2023, the Prime Minister travelled to 11 countries across six trips, costing the exchequer Rs 93.6 crore. In that year, Modi toured Japan, the United States, and France, spending Rs 17.1 crore, Rs 22.8 crore, and Rs 13.74 crore, respectively. In 2021 and 2022, the PM travelled to 14 countries across 10 trips. The two years combined saw the Centre pay out over Rs 90 crore. On the heels of the COVID-19 pandemic, the Prime Minister visited Bangladesh, the US, Italy and the UK across three trips in 2021. In 2022, the PM made seven international visits, covering 10 nations, such as Germany, Denmark, France, Nepal, the UAE, and Indonesia. Over the years, international summits, including the 2021 G20 Summit hosted by Italy, the 2022 G20 Summit in Indonesia, and the 2024 G20 Summit in Brazil, have necessitated many such foreign trips. The PM, during these travels, usually visits another country or two, whenever possible. Other summits the Prime Minister regularly attends include the East Asian Summit and the Association of Southeast Asian Nations (ASEAN) meetings in Southeast Asia. In 2022, the former Vice President of India Jagdeep Dhankhar—instead of the Prime Minister—represented India at these summits, then held in Cambodia. In 2023 and 2024, the PM travelled to Indonesia and the Lao People's Democratic Republic (Lao PDR), respectively, for annual summits. In 2022, Modi visited Uzbekistan for the Shanghai Cooperation Organisation meet of heads of State. He did not attend its 2024 edition. India hosted the SCO in virtual format in 2023. (Edited by Madhurita Goswami) Also Read: India to resume visas for Chinese nationals as thaw continues ahead of likely Modi-Xi meet
Indian Express
an hour ago
- Indian Express
India-UK trade deal: Will export volume of Indian medical devices go up?
Indian Prime Minister Narendra Modi and UK Prime Minister Keir Starmer signed the India-UK free trade agreement on Thursday, allowing wider access to Indian exports in the UK markets. Pharmaceuticals and medical devices will enjoy zero-duty access under this agreement. With most pharmaceuticals and medical devices exported to the UK already being duty-free, industry experts say easing regulatory norms are likely to have a bigger impact in facilitating Indian exports to the UK. What does the trade deal say about the drugs and medical devices sector? The zero-tariff provisions are likely to make Indian generic medicines more cost-effective in the UK market, as per the agreement. 'India exports USD 23.31 billion globally and the UK imports nearly USD 30 billion, but Indian pharma accounts for under USD 1 billion, indicating significant headroom for growth,' the sectoral outcome summary states. When it comes to medical devices, the agreement says that surgical instruments, diagnostic equipment, ECG machines, X-Ray systems among others will not attract any duty. 'This will reduce costs for Indian med-tech companies and make their products more competitive in the UK market,' the agreement says. The agreement adds that India has emerged as a cost-effective alternative to China, given that the UK is trying to move away from reliance on Chinese imports after Brexit and Covid-19. The agreement says: 'Indian manufacturers are poised to emerge as a favoured, cost-effective alternative, especially with zero-duty pricing for medical devices.' What do Indian manufacturers have to say? When it comes to pharmaceuticals, the agreement is unlikely to lead to a sudden, sharp increase in Indian exports to the UK. An industry expert, who did not want to be named, said, 'The pharmaceutical industry is likely to continue growing at its current trajectory — at around 10 per cent every year — because most of the drugs were already exempt from duty in the UK. What will help is easing of the regulatory framework, which will allow more Indian companies to enter the UK market and quickly.' Companies may end up spending thousands of dollars in getting the requisite approvals to sell in the UK. The same is true for medical devices as well. Rajiv Nath, forum coordinator of Association of Indian Medical Device Industry (AiMeD), said, 'Medical devices imported from India by UK were duty-free previously as well, so tariff restrictions were not an issue. It was the time and cost of regulatory approvals that were a challenge.' He added that the industry had previously sought the recognition of approvals granted by the country's apex drug regulator, CDSCO, or voluntary Quality Control of India certification for fast-tracking regulatory approvals in the UK. Nath added that the lowering of the 7.5 per cent duty levied by India on most UK manufactured medical devices would hopefully happen in a phased manner. He added another caution: 'There is a need for strict verification of the rules of origin of the medical devices in order to ensure that products manufactured by a third country are not routed through the UK for the tariff benefit. This is to ensure that India's nascent medical device industry remains competitive.' How many pharmaceutical products does the UK import from India? UK is the second largest importer of Indian pharmaceutical products, having purchased goods worth USD 913.97 million in FY2025. The country accounted for three per cent of all pharmaceutical exports from India. The largest importer of Indian pharmaceuticals continues to be the US, accounting for 34.5 per cent of the total exports, amounting to USD 10,515 million. The most commonly exported products from India are generic versions of small-molecule pills as well as biologicals (medicines derived from living organisms or cells). What's the quantum of medical devices that the UK imports from India? Export of Indian medical devices to the UK went up by 13 per cent in FY24 as compared to the previous year. These devices were worth Rs 1,015 crore, up from Rs 897.4 crore the previous year. The most common exports to the UK were contact lenses, diagnostic reagents, surgical instruments and PPE kits. Anonna Dutt is a Principal Correspondent who writes primarily on health at the Indian Express. She reports on myriad topics ranging from the growing burden of non-communicable diseases such as diabetes and hypertension to the problems with pervasive infectious conditions. She reported on the government's management of the Covid-19 pandemic and closely followed the vaccination programme. Her stories have resulted in the city government investing in high-end tests for the poor and acknowledging errors in their official reports. Dutt also takes a keen interest in the country's space programme and has written on key missions like Chandrayaan 2 and 3, Aditya L1, and Gaganyaan. She was among the first batch of eleven media fellows with RBM Partnership to End Malaria. She was also selected to participate in the short-term programme on early childhood reporting at Columbia University's Dart Centre. Dutt has a Bachelor's Degree from the Symbiosis Institute of Media and Communication, Pune and a PG Diploma from the Asian College of Journalism, Chennai. She started her reporting career with the Hindustan Times. When not at work, she tries to appease the Duolingo owl with her French skills and sometimes takes to the dance floor. ... Read More
